Prof. Dr. Line Bjørge received her medical degree and PhD degree from the University of Bergen and her MBA degree from the Mannheim Business School and ESSEC, Paris. She performed her residency in Obstetrics and Gynecology at Haukeland University Hospital and her postdoc-research training in Bergen, Helsinki and Innsbruck. She serves on the boards of the Oncologist Forum and the Nordic Society of Gynaecological Oncology (NSGO) and is a member of the translational research group in the Gynecologic Cancer Inter-Group (GCIG). She is currently co-director of CCBIO. The focus of her early research work was immune therapy of ovarian cancer with the use of complement-activating monoclonal antibodies. Together with her Finnish mentor, Professor Seppo Meri, she discovered resistance mechanisms and developed methods to overcome them. In the last decade, her research portfolio has been more translational and she has developed a large multidisciplinary research portfolio, entitled “Precision Medicine in Ovarian Cancer” where the aim is to translate data from comprehensive molecular profiling into clinically meaningful strategies to improve prevention and individualized patient care.
